Oscar Health, Inc.

(a) None.

(b) None.

(c)On February 7, 2025, Alessandrea Quane, the Company’sformer Chief Insurance Officer, terminated the Rule 10b5-1 trading arrangement that she had previously entered into for the sale of up to 211,774 shares of the Company’s Class A common stock by August 29, 2025. The arrangement was originally adopted on September 27, 2024 and was intended to satisfy the affirmative defense of Rule 10b5-1(c).

Effective March 1, 2025, the Company adopted the net settlement method to satisfy applicable tax withholding obligations in connection with restricted stock unit awards for senior leadership. In connection with adopting the net settlement method, the following officers of the Company terminated sell-to-cover instructions intended to satisfy the affirmative defense of Rule 10b5-1(c) and that provided for sales of Class A common stock as necessary to cover tax withholding obligations incurred in connection with the vesting or settlement of restricted stock units:

•On February 25, 2025, Scott Blackley, the Company’s Chief Financial Officer, terminated his sell-to-cover instruction that was originally adopted on September 7, 2021.

•On February 25, 2025, Victoria Baltrus, the Company’s Chief Accounting Officer, terminated her sell-to-cover instruction that was originally adopted on September 1, 2022.

•On February 26, 2025, Mark Bertolini, the Company’s Chief Executive Officer, terminated his sell-to-cover instruction that was originally adopted on November 11, 2024.

•On February 27, 2025, Mario Schlosser, the Company’s Chief Technology Officer, terminated his sell-to-cover instruction that was originally adopted on May 21, 2021.

•On March 14, 2025, Adam McAnaney, the Company’s Chief Legal Officer, terminated his sell-to-cover instruction that was originally adopted on February 15, 2025.

•On March 17, 2025, Janet Liang, the Company’s President, terminated her sell-to-cover instruction that was originally adopted on February 15, 2025.